 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| BI 770371 / Boehringer Ingelheim
New P1 trial, Monotherapy: A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone (clinicaltrials.gov) - Feb 4, 2025
P1, N=90, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 770371 / Boehringer Ingelheim
Enrollment open: A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov) - Jan 29, 2025
P2, N=24, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting
- || BI 770371 / Boehringer Ingelheim
New P2 trial: A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov) - Nov 4, 2024
P2, N=24, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | BI 765063 / Boehringer Ingelheim, BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov) - Aug 22, 2024
P1, N=13, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
- || BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (clinicaltrials.gov) - Jul 22, 2024
P1, N=36, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: Mar 2025 --> Jun 2025 Recruiting --> Active, not recruiting
- | BI 765063 / Boehringer Ingelheim, BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov) - May 29, 2024
P1, N=13, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Jan 2025
- | BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (clinicaltrials.gov) - Apr 17, 2024
P1, N=42, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Jan 2025 Trial completion date: Nov 2025 --> Jan 2025 | Trial primary completion date: Mar 2025 --> Jul 2024
- || BI 765063 / Boehringer Ingelheim, BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Trial completion date, Trial primary completion date: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov) - Nov 3, 2023
P1, N=12, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2025 --> Jan 2025 | Trial primary completion date: Mar 2025 --> Jul 2024 N=22 --> 12 | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
- BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Open-label, phase I, dose escalation/expansion trial of the anti-SIRP? monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2270;
P1
Conclusions BI 770371 showed manageable toxicity alone and in combination with ezabenlimab. The trial is ongoing.
- | BI 765063 / Boehringer Ingelheim, BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov) - Jun 16, 2022
P1, N=22, Recruiting, Sponsor: Boehringer Ingelheim
The trial is ongoing. Trial completion date: Mar 2023 --> Jul 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
- || BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (clinicaltrials.gov) - May 24, 2022
P1, N=42, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Mar 2023 --> Jul 2024 | Trial primary completion date: Nov 2022 --> Nov 2023 Not yet recruiting --> Recruiting
- || BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (clinicaltrials.gov) - Apr 13, 2022
P1, N=42, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 765063 / Boehringer Ingelheim, BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov) - Dec 17, 2021
P1, N=22, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || BI 765063 / Boehringer Ingelheim, BI 770371 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
New P1 trial: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov) - Oct 5, 2021
P1, N=22, Not yet recruiting, Sponsor: Boehringer Ingelheim